Figure 2From: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaCONSORT diagram: study CA184-004. *Mandatory TA. CONSORT: Consolidated Standards of Reporting Trials; ICF: informed consent form; PD: progressive disease; TA: tumor assessment; W: study week.Back to article page